Alexion Pharma (ALXN) Tops Q2 EPS by 37c, Offers FY Guidance

Alexion Pharma (NASDAQ: ALXN) reported Q2 EPS of $2.07, $0.37 better than the analyst estimate of $1.70. Revenue for the quarter came in at $1.05 million versus the consensus estimate of $977.68 million.

GUIDANCE:

Alexion Pharma sees FY2018 EPS of $7.00-$7.15, versus the consensus of $7.03. Alexion Pharma sees FY2018 revenue of $3.98-4.01 million, versus the consensus of $4 million.

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• RegenLab targets Nasdaq listing under ticker RGNA as revenues top $29 million
• Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance